VANCOUVER, British Columbia (PRWEB) December 05, 2018
Dr. Nicolas Loebel was a key speaker at The Royal Society of Medicine’s Photodynamic Therapy symposium 2018, London, England. The 2018 PDT symposium was organized by the RSM Professionals, UK PDT Charitable Trust and addressed the scientific basis of PDT and its benefits in clinical practice across a range of applications in oncology and infection treatment and prevention.
Dr. Loebel, President and Chief Technology Officer of Ondine Biomedical Inc., presented the benefits of Photodynamic Therapy in clinical practice bringing over a decade of experience across several PDT applications including periodontal disease, perio-implantitis, chronic sinusitis (with and without polyps) and the prevention of hospital acquired infections such as surgical site infections and ventilator associated pneumonia.
Specializing in product development, research, photochemistry and system integration, Dr. Loebel is a leading expert in the field of antimicrobial Photodynamic Therapy. In 2017, Dr. Nicolas Loebel was the recipient of the International Photodynamic Therapy (IPA) Clinical PDT Research Excellence Award for his work spanning the past 20 years.
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is dedicated to the development of non-antibiotic, anti-infective therapies for a broad-spectrum of bacterial, viral and fungal infections. Ondine’s antimicrobial program utilizes a platform technology called photodisinfection, a light-activated approach being developed to provide rapid antimicrobial efficacy and reduced risk of antibiotic resistance. Over 65 patents in 21 patent families have been granted or are pending covering various aspects of the technology. Ondine’s flagship nasal photodisinfection system, Steriwave™, has been deployed in Canada for several years, and other applications of the photodisinfection platform are under development, including Sinuwave™, a photodisinfection product to treat chronic rhinosinusitis, and an endotracheal tube photodisinfection product designed to reduce the incidence of ventilator-associated pneumonia (VAP).